AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

AstraZeneca AZN announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with resistant hypertension. Patients with treatment-resistant hypertension (rHTN) were administered with baxdrostat (2mg) or placebo on top of standard of care in the study. Data from the Bax24 study showed that treatment with baxdrostat led to a statistically...